These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 35789315)
1. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer. Chen L; Chen Y; Xie Z; Luo J; Wang Y; Zhou J; Huang L; Li H; Wang L; Liu P; Shu M; Zhang W; Ke Z Breast Cancer Res Treat; 2022 Aug; 194(3):517-529. PubMed ID: 35789315 [TBL] [Abstract][Full Text] [Related]
2. Concordance between ER, PR, Ki67, and HER2-low expression in breast cancer by MammaTyper RT-qPCR and immunohistochemistry: implications for the practising pathologist. Badr NM; Zaakouk M; Zhang Q; Kearns D; Kong A; Shaaban AM Histopathology; 2024 Sep; 85(3):437-450. PubMed ID: 38651302 [TBL] [Abstract][Full Text] [Related]
3. ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6. Filipits M; Rudas M; Singer CF; Fitzal F; Bago-Horvath Z; Greil R; Balic M; Lax SF; Halper S; Hulla W; Wu NC; Liu X; Weidler J; Bates M; Hlauschek D; Gnant M; Dubsky P ESMO Open; 2021 Aug; 6(4):100228. PubMed ID: 34371382 [TBL] [Abstract][Full Text] [Related]
4. Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Wu NC; Wong W; Ho KE; Chu VC; Rizo A; Davenport S; Kelly D; Makar R; Jassem J; Duchnowska R; Biernat W; Radecka B; Fujita T; Klein JL; Stonecypher M; Ohta S; Juhl H; Weidler JM; Bates M; Press MF Breast Cancer Res Treat; 2018 Nov; 172(2):327-338. PubMed ID: 30120700 [TBL] [Abstract][Full Text] [Related]
5. Comparison of immunohistochemistry with PCR for assessment of ER, PR, and Ki-67 and prediction of pathological complete response in breast cancer. Sinn HP; Schneeweiss A; Keller M; Schlombs K; Laible M; Seitz J; Lakis S; Veltrup E; Altevogt P; Eidt S; Wirtz RM; Marmé F BMC Cancer; 2017 Feb; 17(1):124. PubMed ID: 28193205 [TBL] [Abstract][Full Text] [Related]
6. Technical validation of an RT-qPCR in vitro diagnostic test system for the determination of breast cancer molecular subtypes by quantification of ERBB2, ESR1, PGR and MKI67 mRNA levels from formalin-fixed paraffin-embedded breast tumor specimens. Laible M; Schlombs K; Kaiser K; Veltrup E; Herlein S; Lakis S; Stöhr R; Eidt S; Hartmann A; Wirtz RM; Sahin U BMC Cancer; 2016 Jul; 16():398. PubMed ID: 27389414 [TBL] [Abstract][Full Text] [Related]
7. Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Wirtz RM; Sihto H; Isola J; Heikkilä P; Kellokumpu-Lehtinen PL; Auvinen P; Turpeenniemi-Hujanen T; Jyrkkiö S; Lakis S; Schlombs K; Laible M; Weber S; Eidt S; Sahin U; Joensuu H Breast Cancer Res Treat; 2016 Jun; 157(3):437-46. PubMed ID: 27220750 [TBL] [Abstract][Full Text] [Related]
8. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. Bastien RR; Rodríguez-Lescure Á; Ebbert MT; Prat A; Munárriz B; Rowe L; Miller P; Ruiz-Borrego M; Anderson D; Lyons B; Álvarez I; Dowell T; Wall D; Seguí MÁ; Barley L; Boucher KM; Alba E; Pappas L; Davis CA; Aranda I; Fauron C; Stijleman IJ; Palacios J; Antón A; Carrasco E; Caballero R; Ellis MJ; Nielsen TO; Perou CM; Astill M; Bernard PS; Martín M BMC Med Genomics; 2012 Oct; 5():44. PubMed ID: 23035882 [TBL] [Abstract][Full Text] [Related]
9. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Du X; Li XQ; Li L; Xu YY; Feng YM Breast Cancer Res Treat; 2013 Feb; 138(1):59-67. PubMed ID: 23397283 [TBL] [Abstract][Full Text] [Related]
10. An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Varga Z; Lebeau A; Bu H; Hartmann A; Penault-Llorca F; Guerini-Rocco E; Schraml P; Symmans F; Stoehr R; Teng X; Turzynski A; von Wasielewski R; Gürtler C; Laible M; Schlombs K; Joensuu H; Keller T; Sinn P; Sahin U; Bartlett J; Viale G Breast Cancer Res; 2017 May; 19(1):55. PubMed ID: 28490348 [TBL] [Abstract][Full Text] [Related]
11. Looking for more reliable biomarkers in breast cancer: Comparison between routine methods and RT-qPCR. Caselli E; Pelliccia C; Teti V; Bellezza G; Mandarano M; Ferri I; Hartmann K; Laible M; Sahin U; Varga Z; Lupi C; Stracci F; Sidoni A PLoS One; 2021; 16(9):e0255580. PubMed ID: 34555047 [TBL] [Abstract][Full Text] [Related]
12. Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study. Schettini F; Saracchini S; Bassini A; Marus W; Corsetti S; Specogna I; Bertola M; Micheli E; Wirtz RM; Laible M; Şahin U; Strina C; Milani M; Aguggini S; Tancredi R; Fiorio E; Sulfaro S; Generali D Breast; 2024 Aug; 76():103753. PubMed ID: 38815444 [TBL] [Abstract][Full Text] [Related]
13. Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx. Sughayer MA; Alhassoon S; Sughayer HM Ann Diagn Pathol; 2020 Aug; 47():151556. PubMed ID: 32592992 [TBL] [Abstract][Full Text] [Related]
14. Macrodissection prior to closed system RT-qPCR is not necessary for estrogen receptor and HER2 concordance with IHC/FISH in breast cancer. Gupta S; Mani NR; Carvajal-Hausdorf DE; Bossuyt V; Ho K; Weidler J; Wong W; Rhees B; Bates M; Rimm DL Lab Invest; 2018 Aug; 98(8):1076-1083. PubMed ID: 29858579 [TBL] [Abstract][Full Text] [Related]
15. Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study. Lopez-Knowles E; Detre S; Hills M; Schuster EF; Cheang MCU; Tovey H; Kilburn LS; Bliss JM; Robertson J; Mallon E; Skene A; Evans A; Smith I; Dowsett M Breast Cancer Res; 2022 Sep; 24(1):61. PubMed ID: 36096872 [TBL] [Abstract][Full Text] [Related]
16. Variability of predictive markers (hormone receptors, Her2, Ki67) and intrinsic subtypes of breast cancer in four consecutive years 2015-2018. Stevanovic L; Choschzick M; Moskovszky L; Varga Z J Cancer Res Clin Oncol; 2019 Dec; 145(12):2983-2994. PubMed ID: 31628534 [TBL] [Abstract][Full Text] [Related]
17. Comparing breast biomarker status between routine immunohistochemistry and FISH studies and Oncotype DX testing, a study of 610 cases. Neely C; You S; Mendoza PM; Aneja R; Sahin AA; Li X Breast J; 2018 Nov; 24(6):889-893. PubMed ID: 30230095 [TBL] [Abstract][Full Text] [Related]
18. Study of ER, PR, HER2/neu, p53, and Ki67 expression in primary breast carcinomas and synchronous metastatic axillary lymph nodes. Khande TA; Joshi AR; Khandeparkar SGS; Kulkarni MM; Gogate BP; Kakade AR; Sahu PD; Khillare CD Indian J Cancer; 2020; 57(2):190-197. PubMed ID: 32445323 [TBL] [Abstract][Full Text] [Related]
19. Estrogen receptor (ER) mRNA expression and molecular subtype distribution in ER-negative/progesterone receptor-positive breast cancers. Itoh M; Iwamoto T; Matsuoka J; Nogami T; Motoki T; Shien T; Taira N; Niikura N; Hayashi N; Ohtani S; Higaki K; Fujiwara T; Doihara H; Symmans WF; Pusztai L Breast Cancer Res Treat; 2014 Jan; 143(2):403-9. PubMed ID: 24337596 [TBL] [Abstract][Full Text] [Related]
20. Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. Wu J; Fang Y; Lin L; Fei X; Gao W; Zhu S; Zong Y; Chen X; Huang O; He J; Zhu L; Chen W; Li Y; Shen K Oncotarget; 2017 Jun; 8(24):38706-38716. PubMed ID: 28404972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]